Proteomics International Laboratories Ltd (AU:PIQ) — Market Cap & Net Worth
Market Cap & Net Worth: Proteomics International Laboratories Ltd (PIQ)
Proteomics International Laboratories Ltd (AU:PIQ) has a market capitalization of $17.53 Million (AU$24.78 Million) as of August 12, 2026. Listed on the AU stock exchange, this Australia-based company holds position #25545 globally and #1100 in its home market, demonstrating a 3.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Proteomics International Laboratories Ltd's stock price AU$0.15 by its total outstanding shares 165183999 (165.18 Million). See Proteomics International Laboratories Lt (PIQ) net asset quality to understand what proportion of total assets are financed by equity.
Proteomics International Laboratories Ltd Market Cap History: 2015 to 2026
Proteomics International Laboratories Ltd's market capitalization history from 2015 to 2026. Data shows change from $33.31 Million to $17.53 Million (-6.49% CAGR). Also see total assets of Proteomics International Laboratories Lt for a full breakdown of the balance sheet.
Proteomics International Laboratories Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Proteomics International Laboratories Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Proteomics International Laboratories Lt stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
79.71x
Proteomics International Laboratories Ltd's market cap is 79.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $29.22 Million | $816.85K | -$1.33 Million | 35.77x | N/A |
| 2017 | $31.56 Million | $925.36K | -$916.48K | 34.10x | N/A |
| 2018 | $44.41 Million | $1.18 Million | -$1.44 Million | 37.75x | N/A |
| 2019 | $31.56 Million | $1.47 Million | -$2.08 Million | 21.50x | N/A |
| 2020 | $92.92 Million | $1.42 Million | -$1.74 Million | 65.29x | N/A |
| 2021 | $142.01 Million | $1.31 Million | -$2.86 Million | 108.33x | N/A |
| 2022 | $111.03 Million | $1.49 Million | -$4.97 Million | 74.55x | N/A |
| 2023 | $104.61 Million | $730.34K | -$6.23 Million | 143.23x | N/A |
| 2024 | $93.50 Million | $892.14K | -$6.38 Million | 104.81x | N/A |
| 2025 | $76.56 Million | $960.39K | -$8.11 Million | 79.71x | N/A |
Competitor Companies of PIQ by Market Capitalization
Companies near Proteomics International Laboratories Ltd in the global market cap rankings as of August 12, 2026. Also see PIQ cash flow metrics for how efficiently the company converts equity into cash flow.
Key companies related to Proteomics International Laboratories Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #548 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #551 globally with a market cap of $49.22 Billion USD ( ₩72.63 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $523.91 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $808.05 |
| #548 | Argen-X | BR:ARGX | $49.55 Billion | €767.00 |
| #551 | Samsung Biologics Co Ltd | KO:207940 | $49.22 Billion | ₩1569000.00 |
Proteomics International Laboratories Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Proteomics International Laboratories Ltd's market cap moved from $33.31 Million to $ 17.53 Million, with a yearly change of -6.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$17.53 Million | -77.10% |
| 2025 | AU$76.56 Million | -18.12% |
| 2024 | AU$93.50 Million | -10.61% |
| 2023 | AU$104.61 Million | -5.79% |
| 2022 | AU$111.03 Million | -21.81% |
| 2021 | AU$142.01 Million | +52.83% |
| 2020 | AU$92.92 Million | +194.44% |
| 2019 | AU$31.56 Million | -28.95% |
| 2018 | AU$44.41 Million | +40.74% |
| 2017 | AU$31.56 Million | +8.00% |
| 2016 | AU$29.22 Million | -12.28% |
| 2015 | AU$33.31 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 11th, 2026 the market cap of Proteomics International Laboratories Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.53 Million USD |
| MoneyControl | $17.53 Million USD |
| MarketWatch | $17.53 Million USD |
| marketcap.company | $17.53 Million USD |
| Reuters | $17.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more